Supernus Pharma (SUPN) Reports Q4 Revenue of $155M
Tweet
Share
E-mailGet Alerts SUPN Hot Sheet
Join SI Premium – FREE
Supernus Pharma (NASDAQ: SUPN) reported Q4 revenue of $155 million versus the consensus estimate of $149.42 million.
GUIDANCE:
Supernus Pharma sees FY2022 revenue of $640-680 million, versus the consensus of $707.32 million.
For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Science Applications Int'l (SAIC) Tops Q2 EPS by 70c
- Getty Realty (GTY) Reiterated at Market Outperform by Citizens Amid Favourable Trends
- RBC Capital Resumes BorgWarner (BWA) at Outperform
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
